VIVUS, Inc. (NASDAQ:VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the second quarter ended June 30, 2014 and provided a business update. Total net revenue was $21.9 million for the second quarter of 2014, compared to $5.5 million for the second quarter of 2013. Of the total revenue for the … Continue reading Trending Stocks : VIVUS Inc. (NASDAQ:VVUS), VeriSign (NASDAQ:VRSN), Oil-Dri Corp. of America (NYSE:ODC), Orbital Sciences Corp. (NYSE:ORB), Telecom Italia S.p.A. (NYSE:TI)